TY - JOUR

T1 - The cost of inflammatory bowel disease in high-income settings

T2 - a Lancet Gastroenterology & Hepatology Commission

AU - Burisch, Johan

AU - Zhao, Mirabella

AU - Odes, Selwyn

AU - De Cruz, Peter

AU - Vermeire, Severine

AU - Bernstein, Charles N.

AU - Kaplan, Gilaad G.

AU - Duricova, Dana

AU - Greenberg, Dan

AU - Melberg, Hans O.

AU - Watanabe, Mamoru

AU - Ahn, Hyeong Sik

AU - Targownik, Laura

AU - Pittet, Valérie E.H.

AU - Annese, Vito

AU - Park, K. T.

AU - Katsanos, Konstantinos H.

AU - Høivik, Marte L.

AU - Krznaric, Zeljko

AU - Chaparro, María

AU - Loftus, Edward V.

AU - Lakatos, Peter L.

AU - Gisbert, Javier P.

AU - Bemelman, Willem

AU - Moum, Bjorn

AU - Gearry, Richard B.

AU - Kappelman, Michael D.

AU - Hart, Ailsa

AU - Pierik, Marieke J.

AU - Andrews, Jane M.

AU - Ng, Siew C.

AU - D'Inca, Renata

AU - Munkholm, Pia

N1 - Publisher Copyright: © 2023 Elsevier Ltd

PY - 2023

Y1 - 2023

N2 - The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers.

AB - The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers.

U2 - 10.1016/S2468-1253(23)00003-1

DO - 10.1016/S2468-1253(23)00003-1

M3 - Review

C2 - 36871566

AN - SCOPUS:85150811491

VL - 8

SP - 458

EP - 492

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 5

ER -